In this region, Granules has a powerful presence in three major markets - Germany, England and France. In the past few years, the main drive of the Company's growth in this market has been its API & PFI business. With the increase in the formulations business opportunities in Europe, GIL's main focus now will be on the finished formulation contacts with the large pharmaceutical companies.

Granules USA Inc. is a 100 percent owned U.S.-based subsidiary that provides existing and prospective customers in U.S. with a direct interface. With FDA and TGA approved manufacturing facilities, we have had a solid platform for growth in this key region.

Granules operations in the United States are conducted through its fully owned subsidiary - Granules USA Inc, which was incorporated in 1987 and has been operating in the US market for over 22 years.

For Granules, Latin America has been an ongoing investment. Today Granules has increased its market share due to the increase in the awareness of market and adoption of competitive marketing strategy and value added technical support. The Company currently has strong presence in four major markets - Colombia, Chile, Brazil and Mexico and is continously expanding its presence in these key markets and other markets in the region.

As part of our global initiative, we are committed to extending our reach and growing our base of partners in Asia. Our joint venture with Biocause Pharmaceuticals in Hubei, China is testament to our commitment to the region, and has proven to be invaluable for Ibuprofen API and PFI sales. We are riding this momentum and increasing our API sales even further in Paracetamol, Metformin, Guaifenesin, Ciprofloxacin and by extension, respective PFI sales. Today, Granules has a strong presence in South Korea, Australia and the Middle East.

We have stayed true to our origins and have built a dominating presence in India based on sustainable and mutual partnerships. As testament, not only do we offer an end-to-end portfolio of products, we customize our products based on customer specifications.